SANDOZ DEFERASIROX DIN 02464470
Health Canada record
| Active ingredient(s) | DEFERASIROX 500 MG |
|---|---|
| Dosage form | Tablet For Suspension |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | V03AC03 DEFERASIROX |
| Original market date | 04-Jul-2017 |
| Current status date | 04-Jul-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DEFERASIROX
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02564939 | ALEMBIC-DEFERASIROX (TYPE J) | ALEMBIC PHARMACEUTICALS LIMITED | Tablet | DEFERASIROX 360 MG | Approved |
| 02461552 | APO-DEFERASIROX | APOTEX INC | Tablet For Suspension | DEFERASIROX 250 MG | Marketed |
| 02461544 | APO-DEFERASIROX | APOTEX INC | Tablet For Suspension | DEFERASIROX 125 MG | Marketed |
| 02461560 | APO-DEFERASIROX | APOTEX INC | Tablet For Suspension | DEFERASIROX 500 MG | Marketed |
| 02485273 | APO-DEFERASIROX (TYPE J) | APOTEX INC | Tablet | DEFERASIROX 180 MG | Marketed |
| 02485265 | APO-DEFERASIROX (TYPE J) | APOTEX INC | Tablet | DEFERASIROX 90 MG | Marketed |
| 02485281 | APO-DEFERASIROX (TYPE J) | APOTEX INC | Tablet | DEFERASIROX 360 MG | Marketed |
| 02527774 | AURO-DEFERASIROX (TYPE J) | AURO PHARMA INC | Tablet | DEFERASIROX 90 MG | Marketed |
| 02527790 | AURO-DEFERASIROX (TYPE J) | AURO PHARMA INC | Tablet | DEFERASIROX 360 MG | Marketed |
| 02527782 | AURO-DEFERASIROX (TYPE J) | AURO PHARMA INC | Tablet | DEFERASIROX 180 MG | Marketed |
| 02527359 | DEFERASIROX (TYPE J) | JUBILANT GENERICS LIMITED | Tablet | DEFERASIROX 180 MG | Approved |
| 02527367 | DEFERASIROX (TYPE J) | JUBILANT GENERICS LIMITED | Tablet | DEFERASIROX 360 MG | Approved |
| 02527340 | DEFERASIROX (TYPE J) | JUBILANT GENERICS LIMITED | Tablet | DEFERASIROX 90 MG | Approved |
| 02287420 | EXJADE | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet For Suspension | DEFERASIROX 125 MG | Marketed |
| 02287439 | EXJADE | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet For Suspension | DEFERASIROX 250 MG | Marketed |
| 02287447 | EXJADE | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet For Suspension | DEFERASIROX 500 MG | Marketed |
| 02452227 | JADENU | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | DEFERASIROX 180 MG | Marketed |
| 02452235 | JADENU | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | DEFERASIROX 360 MG | Marketed |
| 02452219 | JADENU | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | DEFERASIROX 90 MG | Marketed |
| 02549840 | JAMP DEFERASIROX (TYPE J) | JAMP PHARMA CORPORATION | Tablet | DEFERASIROX 180 MG | Marketed |
| 02549832 | JAMP DEFERASIROX (TYPE J) | JAMP PHARMA CORPORATION | Tablet | DEFERASIROX 90 MG | Marketed |
| 02549859 | JAMP DEFERASIROX (TYPE J) | JAMP PHARMA CORPORATION | Tablet | DEFERASIROX 360 MG | Marketed |
| 02474336 | PMS-DEFERASIROX | PHARMASCIENCE INC | Tablet For Suspension | DEFERASIROX 250 MG | Marketed |
| 02474328 | PMS-DEFERASIROX | PHARMASCIENCE INC | Tablet For Suspension | DEFERASIROX 125 MG | Marketed |
| 02474344 | PMS-DEFERASIROX | PHARMASCIENCE INC | Tablet For Suspension | DEFERASIROX 500 MG | Marketed |
| 02528304 | PMS-DEFERASIROX (TYPE J) | PHARMASCIENCE INC | Tablet | DEFERASIROX 180 MG | Marketed |
| 02528290 | PMS-DEFERASIROX (TYPE J) | PHARMASCIENCE INC | Tablet | DEFERASIROX 90 MG | Marketed |
| 02528312 | PMS-DEFERASIROX (TYPE J) | PHARMASCIENCE INC | Tablet | DEFERASIROX 360 MG | Marketed |
| 02464462 | SANDOZ DEFERASIROX | SANDOZ CANADA INCORPORATED | Tablet For Suspension | DEFERASIROX 250 MG | Marketed |
| 02464454 | SANDOZ DEFERASIROX | SANDOZ CANADA INCORPORATED | Tablet For Suspension | DEFERASIROX 125 MG | Marketed |
| 02489910 | SANDOZ DEFERASIROX (TYPE J) | SANDOZ CANADA INCORPORATED | Tablet | DEFERASIROX 360 MG | Marketed |
| 02489899 | SANDOZ DEFERASIROX (TYPE J) | SANDOZ CANADA INCORPORATED | Tablet | DEFERASIROX 90 MG | Marketed |
| 02489902 | SANDOZ DEFERASIROX (TYPE J) | SANDOZ CANADA INCORPORATED | Tablet | DEFERASIROX 180 MG | Marketed |
| 02463520 | TARO-DEFERASIROX | TARO PHARMACEUTICALS INC | Tablet For Suspension | DEFERASIROX 125 MG | Marketed |
| 02463539 | TARO-DEFERASIROX | TARO PHARMACEUTICALS INC | Tablet For Suspension | DEFERASIROX 250 MG | Marketed |
| 02463547 | TARO-DEFERASIROX | TARO PHARMACEUTICALS INC | Tablet For Suspension | DEFERASIROX 500 MG | Marketed |
| 02507331 | TARO-DEFERASIROX (TYPE J) | TARO PHARMACEUTICALS INC | Tablet | DEFERASIROX 360 MG | Marketed |
| 02507323 | TARO-DEFERASIROX (TYPE J) | TARO PHARMACEUTICALS INC | Tablet | DEFERASIROX 180 MG | Marketed |
| 02507315 | TARO-DEFERASIROX (TYPE J) | TARO PHARMACEUTICALS INC | Tablet | DEFERASIROX 90 MG | Marketed |
| 02407973 | TEVA-DEFERASIROX | TEVA CANADA LIMITED | Tablet For Suspension | DEFERASIROX 500 MG | Cancelled Post Market |
| 02407957 | TEVA-DEFERASIROX | TEVA CANADA LIMITED | Tablet For Suspension | DEFERASIROX 125 MG | Cancelled Post Market |
| 02407965 | TEVA-DEFERASIROX | TEVA CANADA LIMITED | Tablet For Suspension | DEFERASIROX 250 MG | Cancelled Post Market |
| 02531291 | TEVA-DEFERASIROX (TYPE J) | TEVA CANADA LIMITED | Tablet | DEFERASIROX 90 MG | Cancelled Pre Market |
| 02531313 | TEVA-DEFERASIROX (TYPE J) | TEVA CANADA LIMITED | Tablet | DEFERASIROX 360 MG | Cancelled Pre Market |
| 02531305 | TEVA-DEFERASIROX (TYPE J) | TEVA CANADA LIMITED | Tablet | DEFERASIROX 180 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 19401 | 2017-06-08 | New Drug Submission (NDS) | LICENSING AGREEEMENT BETWEEN TWO COMPANIES |
International API supply for DEFERASIROX
14 valid EDQM Certificates of Suitability from 14 holders. 22 active FDA Drug Master Files.
Request a quote for SANDOZ DEFERASIROX